Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

被引：0
|
作者：
Arnold Bolomsky
Karin Schlangen
Wolfgang Schreiner
Niklas Zojer
Heinz Ludwig
机构：
[1] Department of Medicine I,Wilhelminen Cancer Research Institute
[2] Wilhelminenspital,Center for Medical Statistics, Informatics and Intelligent Systems
[3] Medical University of Vienna,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Multiple myeloma; BMI-1; PTC-209; Microenvironment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 36 条
  • [1] Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
    Bolomsky, Arnold
    Schlangen, Karin
    Schreiner, Wolfgang
    Zojer, Niklas
    Ludwig, Heinz
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH & SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT
    Bolomsky, A.
    Schlangen, K.
    Schreiner, W.
    Zojer, N.
    Ludwig, H.
    HAEMATOLOGICA, 2016, 101 : 251 - 252
  • [3] PTC-209, A TRANSCRIPTIONAL SMALL MOLECULE INHIBITOR OF BMI-1, DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO
    Bolomsky, A.
    Ludwig, H.
    HAEMATOLOGICA, 2015, 100 : 77 - 78
  • [4] Targeting of BMI-1 with PTC-209 inhibits glioblastoma development
    Kong, Yu
    Ai, Chunbo
    Dong, Feng
    Xia, Xianyou
    Zhao, Xiujuan
    Yang, Chao
    Kang, Chunsheng
    Zhou, Yan
    Zhao, Qian
    Sun, Xiujing
    Wu, Xudong
    CELL CYCLE, 2018, 17 (10) : 1199 - 1211
  • [5] The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
    Alzrigat, Mohammad
    Parraga, Alba Atienza
    Majumder, Muntasir Mamun
    Ma, Anqi
    Jin, Jian
    Osterborg, Anders
    Nahi, Hareth
    Nilsson, Kenneth
    Heckman, Caroline A.
    Oberg, Fredrik
    Kalushkova, Antonia
    Jernberg-Wiklund, Helena
    ONCOTARGET, 2017, 8 (61) : 103731 - 103743
  • [6] BMI-1 inhibition by PTC-209 induces mitochondrial apoptosis in acute myeloid leukemia cells
    Kojima, Kensuke
    Nishida, Yuki
    Maeda, Aya
    Chachad, Dhruv
    Kitamura, Hiroaki
    Ishizawa, Jo
    Andreeff, Michael
    Kimura, Shinya
    CANCER RESEARCH, 2015, 75
  • [7] Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment
    Zhou, Jihao
    Shen, Qi
    Lin, Haiqing
    Hu, Lina
    Li, Guoqiang
    Zhang, Xinyou
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) : 329 - 336
  • [8] Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment
    Jihao Zhou
    Qi Shen
    Haiqing Lin
    Lina Hu
    Guoqiang Li
    Xinyou Zhang
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 329 - 336
  • [9] Glucose and Cell Context-Dependent Impact of BMI-1 Inhibitor PTC-209 on AKT Pathway in Endometrial Cancer Cells
    Zaczek, Agnieszka
    Szustka, Aleksandra
    Krzeslak, Anna
    CANCERS, 2022, 14 (23)
  • [10] The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene
    Bolomsky, Arnold
    Muller, Josephine
    Stangelberger, Kathrin
    Lejeune, Margaux
    Duray, Elodie
    Breid, Helene
    Vrancken, Louise
    Pfeiffer, Christina
    Huebl, Wolfgang
    Willheim, Martin
    Weetall, Marla
    Branstrom, Art
    Zojer, Nildas
    Caers, Jo
    Ludwig, Heinz
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (06) : 877 - 890
1234